HeartSciences Inc. (NASDAQ: HSCS)

HeartSciences is a medical technology company focused on applying artificial intelligence to electrocardiogram ECG technology to enhance its clinical utility for detecting a broader range of heart conditions. The company develops AI ECG algorithms that are designed to identify cardiac dysfunction and other conditions that traditionally require imaging such as echocardiogram. These algorithms are integrated into its proprietary MyoVista wav ECG device which combines a standard 12 lead resting ECG with the AI ECG algorithm and also includes the Glasgow Algorithm for conventional ECG interpretation. In addition HeartSciences is building a cloud based platform the MyoVista Insights Cloud Platform that is intended to be hardware agnostic allowing existing ECG devices to upload data and receive AI ECG analysis from the company's internally developed algorithms or from third party contributors. The platform aims to provide efficient review reporting and storage of recorded ECGs while creating an marketplace for AI ECG algorithms. Neither the MyoVista wav ECG device the MyoVista Insights Cloud Platform nor any of the AI ECG algorithms have yet received clearance for marketing from the U S Food and Drug Administration. The company’s immediate goal is to obtain FDA clearance for its products and then launch them in clinical settings ranging from large health systems to frontline points of care such as primary care clinics.

HeartSciences intends to generate revenue primarily through the sale of its MyoVista wav ECG device under a razor and blade model where the device is sold together with proprietary electrodes that must be replaced after each test. In addition the company plans to earn recurring revenue from the use of its AI ECG algorithms either through usage fees or subscriptions via the MyoVista Insights Cloud Platform. The cloud platform is expected to charge fees for hosting the company's own AI ECG algorithms as well as for providing access to third party AI ECG algorithms that have obtained regulatory clearance. HeartSciences also anticipates that once its algorithms receive FDA clearance they will be eligible for reimbursement from third party payors including the Centers for Medicare and Medicaid Services and that the company will pursue appropriate CPT codes to facilitate billing. The initial commercial focus will be the United States and European markets where the company will employ a direct sales force in the United States and rely on medical device distributors with established healthcare relationships in Europe and other regions. The company believes that the combination of device sales consumable sales and algorithm based recurring revenue will create a diversified revenue stream as it expands its product offering.

The AI enhanced cardiac diagnostics market is emerging as a response to the limitations of conventional electrocardiography which has limited sensitivity in detecting structural and ischemic heart disease. According to the American Heart Association heart disease remains the leading cause of death in the United States with one person dying from cardiovascular disease every 34 seconds and annual costs exceeding 240 billion dollars. The global ECG market is projected to grow from approximately 10.93 billion dollars in 2023 to about 30.87 billion dollars in 2034 indicating strong demand for ECG related products. Despite this widespread use traditional ECGs often fail to detect early signs of disease such as impaired cardiac relaxation which is an early indicator of diastolic dysfunction and can precede symptoms by many years. HeartSciences seeks to close this diagnostic gap by adding AI ECG capability to the standard ECG test thereby enabling earlier detection of conditions such as low ejection fraction and diastolic dysfunction. Competitors in the space include established ECG manufacturers like GE Healthcare Philips and Nihon Kohden as well as newer artificial intelligence focused companies such as Anumana Tempus Labs and VIZ ai. The company’s competitive advantage stems from its proprietary AI ECG algorithms that aim to detect cardiac dysfunction without requiring new hardware and from its cloud based platform that allows existing ECG devices to access advanced analytics reducing the need for capital investment by healthcare providers.

The company serves a broad range of healthcare providers including hospitals health systems primary care clinics cardiology practices urgent care centers retail clinics and telemedicine settings. Early adopter pilots have already been established at two undisclosed medical institutions to test the MyoVista Insights Cloud Platform and integrate it into clinical workflows. HeartSciences intends to focus its sales efforts on health systems and large provider networks that can benefit from improved cardiac referral pathways and reduced reliance on costly imaging studies. In addition the company plans to target insurers and managed care organizations that have high enrollment in Medicare Advantage plans because there is a financial incentive to identify sicker patients earlier. The company also sees opportunities in specialty environments such as cardiology oncology drug trials and athlete screening programs where early detection of cardiac dysfunction can inform treatment decisions. Ultimately HeartSciences aims to provide its AI ECG solutions to any setting where a standard ECG is performed ranging from physician offices to emergency departments.